A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo

Pan, Ya-min; Zhang, Ying; Li, Jiaqi; Zeng, Zhen; He, Yanming; Zhao, Qing; Yang, Hongjie; Zhou, Ping

doi:10.1016/j.jep.2023.116405

Cited by 9 publications

(8 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deficiency of AKT2 and GLUT-4 leads to type 2 diabetes and insulin resistance [ 51 , 53 ]. The relative study and results have been reported by Pan et al (see Figure S 1 and S 2 in Supplementary materials) [ 34 , 54 ].…”

Section: Resultssupporting

confidence: 57%

Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum

Wang

Zheng

et al. 2023

Lipids Health Dis

Self Cite

View full text Add to dashboard Cite

Obesity is often accompanied by metabolic disorder and insulin resistance, resulting in type 2 diabetes. Based on previous findings, FYGL, a natural hyperbranched proteoglycan extracted from the G. lucidum fruiting body, can decrease blood glucose and reduce body weight in diabetic mice. In this article, the underlying mechanism of FYGL in ameliorating obesity-induced diabetes was further investigated both in vivo and in vitro. FYGL upregulated expression of metabolic genes related to fatty acid biosynthesis, fatty acid β-oxidation and thermogenesis; downregulated the expression of insulin resistance-related genes; and significantly increased the number of beige adipocytes in db/db mice. In addition, FYGL inhibited preadipocyte differentiation of 3T3-L1 cells by increasing the expression of FABP-4. FYGL not only promoted fatty acid synthesis but also more significantly promoted triglyceride degradation and metabolism by activating the AMPK signalling pathway, therefore preventing fat accumulation, balancing adipocyte production and lipid metabolism, and regulating metabolic disorders and unhealthy obesity. FYGL could be used as a promising pharmacological agent for the treatment of metabolic disorder-related obesity.

show abstract

Section: Resultssupporting

confidence: 57%

Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum

Wang

Zheng

et al. 2023

Lipids Health Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Increased purple color in the model group after PAS staining indicated the deposition of glycogen in the kidneys, reflecting the glomerular basement membrane thickened and mesangial matrix expansion. Masson stained-kidneys showed an increase in blue color, indicating a large amount of collagen fibronectin deposition, which proved the interstitial fibrosis in the kidneys [ 3 ]. Our study showed that Mudan granules reduced urinary albumin, ameliorated SCr and BUN, and alleviated the pathological renal lesion in rats, suggesting the protective role of Mudan granules in the renal fibrosis of diabetic rats [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…The progressive accumulation of extracellular matrix (ECM) components led to kidney fibrosis. Evidence indicates that collagen, FN, and LN increase significantly in diabetes-induced renal fibrosis [ 3 , 5 , 23 ]. Our study found that Mudan granules treatment during the last 12 weeks significantly inhibited T1DM-induced collagen, FN, and LN expression.…”

Section: Discussionmentioning

confidence: 99%

“…Diabetes nephropathy is the main cause of end-stage renal nephropathy, and more and more patients with diabetes nephropathy develop end-stage renal disease [ 2 ]. During the progression of disease, continuous hyperglycemia will lead to abnormal glomerular blood flow stability, abnormal vascular permeability, and extracellular matrix (ECM) deposition, eventually leading to glomerulosclerosis and renal fibrosis [ 3 ]. Therefore, the inhibition of glomerulosclerosis and renal fibrosis is an effective strategy to prevent DN from developing into end-stage nephropathy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study on effects and relevant mechanisms of Mudan granules on renal fibrosis in streptozotocin-induced diabetes rats

Qi,

Hu,

Zhu

et al. 2024

Renal Failure

View full text Add to dashboard Cite

Aims The effects and relevant mechanisms of Mudan granules in the renal fibrosis of diabetic rats were explored through in vivo experiments, which provided a scientific basis for expanding their clinical indications. Methods Male SD rats were given a single intraperitoneal injection of STZ (65 mg/kg) to induce diabetes rat models. After treatment with Mudan granules, the general condition of rats was recorded. Blood glucose, blood lipids, and renal function-related indicators were detected, renal tissue morphological changes and fibrosis-related indicators were observed, and the expression of pathway-related proteins were examined. Results The general condition of diabetes rats was improved after the treatment of Mudan granules, the 24-h urinary protein and urinary albumin to creatinine ratio were reduced, and the renal function and lipid results were modified. The tissue damage to the rat kidney has been repaired. Expression of TGF-β1/Smad-related pathway proteins was suppressed in kidney tissues, and the fibrosis factor CO-IV, FN, and LN were reduced in serum. Conclusion Mudan granules may inhibit of TGF-β1/Smad pathway, inhibit the production of ECM, reduce the levels of fibrosis factors CO-IV, FN, and LN, to have a protective effect on kidney in diabetes rats.

show abstract

“…FYGL significantly inhibited HG/PA-induced proliferation of HBZY-1 cells, ROS generation, and malondialdehyde (MDA) production; promoted Superoxide Dismutase(SOD) activity; and suppressed the expression of NADPH oxidase 1(NOX1), NADPH oxidase 4(NOX4), mitogen-activated protein kinase, NF-κB, and pro-fibronectin expression. It significantly alleviates lipid metabolism disorders and protects the kidneys from oxidative stress-induced dysfunction, delaying DKD ( 209 ).…”

Section: Targeting Lipid Metabolism For Dkd Treatmentmentioning

confidence: 99%

Lipid metabolism disorder in diabetic kidney disease

Han,

Du,

Zhu

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetic kidney disease (DKD), a significant complication associated with diabetes mellitus, presents limited treatment options. The progression of DKD is marked by substantial lipid disturbances, including alterations in triglycerides, cholesterol, sphingolipids, phospholipids, lipid droplets, and bile acids (BAs). Altered lipid metabolism serves as a crucial pathogenic mechanism in DKD, potentially intertwined with cellular ferroptosis, lipophagy, lipid metabolism reprogramming, and immune modulation of gut microbiota (thus impacting the liver-kidney axis). The elucidation of these mechanisms opens new potential therapeutic pathways for DKD management. This research explores the link between lipid metabolism disruptions and DKD onset.

show abstract

A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo

Cited by 9 publications

References 59 publications

Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum

Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum

Study on effects and relevant mechanisms of Mudan granules on renal fibrosis in streptozotocin-induced diabetes rats

Lipid metabolism disorder in diabetic kidney disease

Contact Info

Product

Resources

About